Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/36865
Title: | Factors associated with anaemia in kidney transplant recipients in the first year after transplantation: A cross-sectional study. | Authors: | Lim A.K.H.;Kanellis J.;Kansal A. | Institution: | (Lim, Kansal, Kanellis) Department of Nephrology, Monash Health, Clayton, VIC 3168, Australia (Lim, Kanellis) Department of Medicine, Monash University, Clayton, VIC 3168, Australia | Issue Date: | 16-Oct-2018 | Copyright year: | 2018 | Publisher: | BioMed Central Ltd. (E-mail: info@biomedcentral.com) | Place of publication: | United Kingdom | Publication information: | BMC Nephrology. 19 (1) (no pagination), 2018. Article Number: 252. Date of Publication: 05 Oct 2018. | Journal: | BMC Nephrology | Abstract: | Background: Anaemia after kidney transplantation may reduce quality of life, graft or patient survival. We aimed to determine the prevalence and risk factors for anaemia in the initial 12 months after transplantation. Method(s): We conducted a cross-sectional study at 6 and 12 months after transplantation. Anaemia was defined by World Health Organization criteria taking into consideration erythropoietin use. Logistic regression was used to determine the association between demographic, clinical and pharmacological risk factors for the main outcome of moderate-severe anaemia. Result(s): A total of 336 transplant recipients were included and the prevalence of moderate-severe anaemia was 27.4% at 6 months and 15.2% at 12 months. Lower kidney function, female gender, transferrin saturation below 10% and proteinuria were associated with moderate-severe anaemia at both time points. Recent intravenous immunoglobulin treatment was associated with anaemia at 6 months. Recent infection and acute rejection were also associated with anaemia 12 months. Around 20% of patients had at least one blood transfusion but they were uncommon beyond 3 months. Conclusion(s): Anaemia remains highly prevalent requiring treatment with erythropoietin and transfusions. Most identifiable risk factors relate to clinical problems rather than pharmacological management, while markers of iron-deficiency remain difficult to interpret in this setting.Copyright © 2018 The Author(s). | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1186/s12882-018-1054-7 | Link to associated publication: | Click here for full text options | PubMed URL: | 30290796 [http://www.ncbi.nlm.nih.gov/pubmed/?term=30290796] | ISSN: | 1471-2369 (electronic) | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/36865 | Type: | Article | Subjects: | article blood transfusion cross-sectional study disease association disease severity dosage schedule comparison drug dose reduction female gender graft infection/co [Complication] *graft recipient human iron deficiency *kidney pancreas transplantation major clinical study male *prevalence proteinuria *risk factor acetylsalicylic acid/cb [Drug Combination] acetylsalicylic acid/dt [Drug Therapy] anticoagulant agent/dt [Drug Therapy] antithrombocytic agent/cb [Drug Combination] antithrombocytic agent/dt [Drug Therapy] basiliximab/dt [Drug Therapy] clopidogrel/dt [Drug Therapy] cotrimoxazole/do [Drug Dose] cotrimoxazole/dt [Drug Therapy] cyclosporine/dt [Drug Therapy] erythropoietin/dt [Drug Therapy] immunoglobulin G/dt [Drug Therapy] immunoglobulin G/iv [Intravenous Drug Administration] tacrolimus/dt [Drug Therapy] transferrin/ec [Endogenous Compound] valganciclovir/do [Drug Dose] valganciclovir/dt [Drug Therapy] warfarin/dt [Drug Therapy] kidney function iron/dt [Drug Therapy] iron/iv [Intravenous Drug Administration] iron/po [Oral Drug Administration] mycophenolate mofetil/dt [Drug Therapy] prednisolone/dt [Drug Therapy] proton pump inhibitor/do [Drug Dose] proton pump inhibitor/dt [Drug Therapy] acute graft rejection/di [Diagnosis] acute graft rejection/dt [Drug Therapy] acute graft rejection/th [Therapy] adult *anemia/co [Complication] *anemia/di [Diagnosis] *anemia/dt [Drug Therapy] *anemia/th [Therapy] *graft recipient human iron deficiency kidney function *kidney pancreas transplantation major clinical study male *prevalence proteinuria blood transfusion Article *anemia / *complication / *diagnosis / *drug therapy / *therapy adult acute graft rejection / diagnosis / drug therapy / therapy *risk factor cross-sectional study disease association disease severity dosage schedule comparison drug dose reduction female gender graft infection / complication |
Type of Clinical Study or Trial: | Observational study (cohort, case-control, cross sectional or survey) |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.